UB-612 is a COVID-19 vaccine candidate developed by , and Vaxxinity, Inc. It is a peptide vaccine.
UB-612 is a COVID-19 vaccine candidate developed by , and Vaxxinity, Inc. It is a peptide vaccine.
It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern. Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).